M
Masaaki Suzuki
Researcher at Gifu University
Publications - 199
Citations - 7460
Masaaki Suzuki is an academic researcher from Gifu University. The author has contributed to research in topics: Insulin resistance & Essential hypertension. The author has an hindex of 46, co-authored 187 publications receiving 7169 citations. Previous affiliations of Masaaki Suzuki include Pfizer & Nagoya University.
Papers
More filters
Journal ArticleDOI
A facile procedure for acetalization under aprotic conditions
TL;DR: Carbonyl compounds are readily acetalized by alkoxysilanes in the presence of trimethylsilyl trifluoromethanesulfonate catalyst.
Journal ArticleDOI
Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic [correction of electrophillic] phase II inducers.
Takumi Satoh,Shu Ichi Okamoto,Jiankun Cui,Yasuyoshi Watanabe,K. Furuta,Masaaki Suzuki,K. Tohyama,Stuart A. Lipton +7 more
TL;DR: The results suggest that NEPPs prevent excitotoxicity by activating the Keap1/Nrf2/HO-1 pathway, and may provide a category of neuroprotective compounds, distinct from other electrophilic compounds such as tert-butylhydroquinone, which activates the antioxidant-responsive element in astrocytes.
Journal ArticleDOI
Trimethysilyl triflate in organic synthesis11Part 11 of this series. Part 10: S. Murata and R. Noyori, Tetrahedron Letters 2107 (1981).
TL;DR: Trimethylsilyl triflate is a powerful silylating agent for organic compounds and acts as a catalyst which accelerates a variety of nucleophilic reactions in aprotic media as discussed by the authors.
Journal ArticleDOI
Manipulation of Alternative Splicing by a Newly Developed Inhibitor of Clks
Michiko Muraki,Bisei Ohkawara,Takamitsu Hosoya,Hiroshi Onogi,Jun Koizumi,Tomonobu Koizumi,Kengo Sumi,Jun-ichiro Yomoda,Michael V. Murray,Hiroshi Kimura,Kiyoshi Furuichi,Hiroshi Shibuya,Adrian R. Krainer,Masaaki Suzuki,Masatoshi Hagiwara +14 more
TL;DR: TG003, a novel inhibitor of Clk family will be a valuable tool to dissect the regulatory mechanisms involving serine/arginine-rich protein phosphorylation signaling pathways in vivo, and may be applicable for the therapeutic manipulation of abnormal splicing.
Journal ArticleDOI
The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway.
TL;DR: The results show that the Rho-kinase inhibitor targets a protein with a well-known function, MARC KS in neuronal cells, and raises the possibility that MARCKS is a target protein of Rho -kinase in neuronal Cells.